B. Riley keeps a Buy rating on Ovid Therapeutics (OVID) with a $3 price target following a transfer of coverage. The firm views OV329 as a “best-in-class contender” that could increase investor optimism.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics management to meet with B. Riley
- Ovid Therapeutics Approves Key Proposals at Annual Meeting
- Ovid Therapeutics Sells Ganaxolone Royalties to Immedica
- Ovid enters agreement with Immedica for sale of future ganaxolone royalties
- Ovid Therapeutics: Promising Buy Opportunity with OV329 Advancements in Drug-Resistant Epilepsy